Cognition Therapeutics, Inc. announced that the last participant was randomized in the Phase 2 SHINE study (NCT03507790) of CT1812, the company's lead candidate for the treatment of age-related neurodegenerative diseases of the CNS and retina. A total of 153 adults with mild-to-moderate (MMSE 18-26) Alzheimer's disease were randomized to receive either placebo or oral doses of CT1812 (100 mg or 300 mg). An evaluation of the first 24 SHINE participants showed that those treated with CT1812 experienced a slowing of cognitive decline as measured by a three-point difference on the ADAS-Cog 11 scale compared to placebo.

Overall, CT1812 was well tolerated and adverse events were balanced across treatment groups, consistent with the safety profile observed in previous clinical trials. The SHINE study was supported by two grant awards from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million.